Citations (64)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (15)
Chrysoula Boutari, Asterios Karagiannis & Vasilios G. Athyros. (2021) Rosuvastatin and ezetimibe for the treatment of dyslipidemia and hypercholesterolemia. Expert Review of Cardiovascular Therapy 19:7, pages 575-580.
Read now
Read now
Dujrudee Chinwong, Jayanton Patumanond, Surarong Chinwong, Khanchai Siriwattana, Siriluck Gunaparn, John Joseph Hall & Arintaya Phrommintikul. (2015) Statin therapy in patients with acute coronary syndrome: low-density lipoprotein cholesterol goal attainment and effect of statin potency. Therapeutics and Clinical Risk Management 11, pages 127-136.
Read now
Read now
Aris P Agouridis, Michael S Kostapanos & Moses S Elisaf. (2015) Statins and their increased risk of inducing diabetes. Expert Opinion on Drug Safety 14:12, pages 1835-1844.
Read now
Read now
Mario J.N.M. Ouwens, Jos Nauta, Jean-Claude Ansquer & Stefan Driessen. (2015) Systematic literature review and meta-analysis of dual therapy with fenofibrate or fenofibric acid and a statin versus a double or equivalent dose of statin monotherapy. Current Medical Research and Opinion 31:12, pages 2273-2285.
Read now
Read now
Aris P Agouridis, Devaki R Nair & Dimitri P Mikhailidis. (2015) Strategies to overcome statin intolerance. Expert Opinion on Drug Metabolism & Toxicology 11:6, pages 851-855.
Read now
Read now
Aris P. Agouridis & Dimitri P. Mikhailidis. (2015) Should we consider ezetimibe to reach even lower LDL-C targets?. Current Medical Research and Opinion 31:3, pages 459-460.
Read now
Read now
Antonio M Gotto$suffix/text()$suffix/text() & Jennifer E Moon. (2015) Twenty-five years of statins: where do we go from here?. Clinical Lipidology 10:1, pages 33-45.
Read now
Read now
Fotios Barkas, Haralampos Milionis, Michael S. Kostapanos, Dimitri P. Mikhailidis, Moses Elisaf & Evangelos Liberopoulos. (2015) How effective are the ESC/EAS and 2013 ACC/AHA guidelines in treating dyslipidemia? Lessons from a lipid clinic. Current Medical Research and Opinion 31:2, pages 221-228.
Read now
Read now
Niki Katsiki, Vasilios G. Athyros & Asterios Karagiannis. (2014) Achieving lipid targets in primary care settings. Current Medical Research and Opinion 30:10, pages 1971-1974.
Read now
Read now
Juergen R Schaefer, Anselm K Gitt, Frank Sonntag, Achim Weizel, Christina Jannowitz, Barbara Karmann, David Pittrow & Kurt Bestehorn. (2013) Lipid management in 13,000 high risk cardiovascular patients treated under daily practice conditions: LIMA Registry. Vascular Health and Risk Management 9, pages 71-80.
Read now
Read now
Julian P Halcox. (2013) Cardiovascular risk and lipid management beyond statin therapy: the potential role of omega–3 polyunsaturated fatty acid ethyl esters. Clinical Lipidology 8:3, pages 329-344.
Read now
Read now
Sheila A Doggrell. (2012) The ezetimibe controversy – can this be resolved by comparing the clinical trials with simvastatin and ezetimibe alone and together?. Expert Opinion on Pharmacotherapy 13:10, pages 1469-1480.
Read now
Read now
Michael S. Kostapanos, Vasilios G. Athyros, Asterios Karagiannis & Dimitri P. Mikhailidis. (2012) Therapeutic options for statin-intolerant patients. Current Medical Research and Opinion 28:3, pages 345-349.
Read now
Read now
Dimitri P. Mikhailidis, Richard W. Lawson, Anna-Louise McCormick, Gillian C. Sibbring, Andrew M. Tershakovec, Glenn M. Davies & Kaan Tunceli. (2011) The role of ezetimibe in LDL cholesterol goal attainment in very high risk patients. Current Medical Research and Opinion 27:10, pages 1961-1961.
Read now
Read now
Laszlo Mark, György Paragh & Istvan Reiber. (2011) The role of ezetimibe in LDL cholesterol goal attainment in very high risk patients: the rosuvastatin monotherapy looks to be insufficient. Current Medical Research and Opinion 27:10, pages 1959-1960.
Read now
Read now
Articles from other publishers (49)
Ruping Cai, Chen Chang, Xingjie Zhong & Qiang Su. (2023) Lowering of Blood Lipid Levels with a Combination of Pitavastatin and Ezetimibe in Patients with Coronary Heart Disease: A Meta-Analysis. Cardiovascular Innovations and Applications 7:1.
Crossref
Crossref
Han Saem Jeong, Soon Jun Hong, Jin-Man Cho, Ki Hoon Han, Dong-Hun Cha, Sang-Ho Jo, Hyun-Jae Kang, So-Yeon Choi, Cheol Ung Choi, Eun Jeong Cho, Young-Hoon Jeong, Hyeon-Cheol Gwon, Byeong-Keuk Kim, Sung Yun Lee, Sang-Hyun Kim, Jeong Cheon Ahn, Young Joon Hong, Woo-Shik Kim, Seong-Ill Woo, Tae-Ho Park & Kyoo-Rok Han. (2022) A Multicenter, Randomized, Double-blind, Active-controlled, Factorial Design, Phase III Clinical Trial to Evaluate the Efficacy and Safety of Combination Therapy of Pitavastatin and Ezetimibe Versus Monotherapy of Pitavastatin in Patients With Primary Hypercholesterolemia. Clinical Therapeutics 44:10, pages 1310-1325.
Crossref
Crossref
Litong Qi, Shuiping Zhao, Jiyan Chen, Mei Zhang, Xiaodong Li, Yugang Dong, Xiaomei Guo, Kai Huang, Fang Wang, Yong Huo & Junbo Ge. (2022) Efficacy and safety of hybutimibe on primary hypercholesterolemia: a randomized, double-blinded, placebo and positive–controlled, parallel phase II study. Cardiology Plus 7:2, pages 77-84.
Crossref
Crossref
Alberico L. Catapano, Michal Vrablik, Yuri Karpov, Baptiste Berthou, Megan Loy & Marie Baccara-Dinet. (2022) A Phase 3 Randomized Controlled Trial to Evaluate Efficacy and Safety of New-Formulation Zenon (Rosuvastatin/Ezetimibe Fixed-Dose Combination) in Primary Hypercholesterolemia Inadequately Controlled by Statins. Journal of Cardiovascular Pharmacology and Therapeutics 27, pages 107424842211382.
Crossref
Crossref
Maciej Banach, Paweł Burchardt, Krzysztof Chlebus, Piotr Dobrowolski, Dariusz Dudek, Krzysztof Dyrbuś, Mariusz Gąsior, Piotr Jankowski, Jacek Jóźwiak, Longina Kłosiewicz-Latoszek, Irina Kowalska, Maciej Małecki, Aleksander Prejbisz, Michał Rakowski, Jacek Rysz, Bogdan Solnica, Dariusz Sitkiewicz, Grażyna Sygitowicz, Grażyna Sypniewska, Tomasz Tomasik, Adam Windak, Dorota Zozulińska-Ziółkiewicz & Barbara Cybulska. (2021) 2021 PoLA/CFPiP/PCS/PSLD/PSD/PSH guidelines on the diagnosis and therapy of lipid disorders in Poland. Diagnostyka Laboratoryjna 57:1, pages 1-99.
Crossref
Crossref
Zlatko Fras & Dimitri P. Mikhailidis. (2021) Have We Learnt all from IMPROVE-IT? Part I. Core Results and Subanalyses on the Effects of Ezetimibe Added to Statin Therapy Related to Age, Gender and Selected Chronic Diseases (Kidney Disease, Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease). Current Vascular Pharmacology 19:5, pages 451-468.
Crossref
Crossref
Fadia Tohme Shaya, Krystal Sing, Robert Milam, Fasahath Husain, Michael A. del Aguila & Miraj Y. Patel. (2019) Lipid-Lowering Efficacy of Ezetimibe in Patients with Atherosclerotic Cardiovascular Disease: A Systematic Review and Meta-Analyses. American Journal of Cardiovascular Drugs 20:3, pages 239-248.
Crossref
Crossref
Antonio Carlos Amedeo Vattimo, Francisco Antonio Helfestein Fonseca, Douglas Costa Morais, Larissa Fontes Generoso, Renata Herrera, Cristiane Moraes Barbosa, Maria Cristina de Oliveira Izar, Rita Antonelli Cardoso & Stevin Zung. (2020) Efficacy and Tolerability of a Fixed-Dose Combination of Rosuvastatin and Ezetimibe Compared with a Fixed-Dose Combination of Simvastatin and Ezetimibe in Brazilian Patients with Primary Hypercholesterolemia or Mixed Dyslipidemia: A Multicenter, Randomized Trial. Current Therapeutic Research 93, pages 100595.
Crossref
Crossref
Juan Pedro-Botet & Xavier Pintó. (2019) Colesterol LDL, cuanto más bajo mejor. Clínica e Investigación en Arteriosclerosis 31, pages 16-27.
Crossref
Crossref
Maria Lorenzi, Baishali Ambegaonkar, Carl A. Baxter, Jeroen Jansen, Michael J. Zoratti & Glenn Davies. (2018) Ezetimibe in high-risk, previously treated statin patients: a systematic review and network meta-analysis of lipid efficacy. Clinical Research in Cardiology 108:5, pages 487-509.
Crossref
Crossref
Andromachi Reklou, Michael Doumas, Konstantinos Imprialos, Konstantinos Stavropoulos, Dimitris Patoulias & Vasilios G. Athyros. (2018) Reduction of Vascular Inflammation, LDL-C, or Both for the Protection from Cardiovascular Events?. The Open Cardiovascular Medicine Journal 12:1, pages 29-40.
Crossref
Crossref
Peter Fraunberger, Elisabeth Gröne, Hermann-Josef Gröne, Heinz Drexel & Autar K. Walli. (2017) Ezetimibe reduces cholesterol content and NF-kappaB activation in liver but not in intestinal tissue in guinea pigs. Journal of Inflammation 14:1.
Crossref
Crossref
Jeffrey E Ming, Ruth E Abrams, Derek W Bartlett, Mengdi Tao, Tu Nguyen, Howard Surks, Katherine Kudrycki, Ananth Kadambi, Christina M Friedrich, Nassim Djebli, Britta Goebel, Alex Koszycki, Meera Varshnaya, Joseph Elassal, Poulabi Banerjee, William J Sasiela, Michael J Reed, Jeffrey S Barrett & Karim Azer. (2017) A Quantitative Systems Pharmacology Platform to Investigate the Impact of Alirocumab and Cholesterol-Lowering Therapies on Lipid Profiles and Plaque Characteristics. Gene Regulation and Systems Biology 11, pages 117762501771094.
Crossref
Crossref
Yulia Treister-Goltzman & Roni Peleg. (2016) A Descriptive Analysis of Changes in Selected Drug Groups Available to Primary Care Physicians in Israel From 2000 to 2013. American Journal of Therapeutics 23:6, pages e1335-e1343.
Crossref
Crossref
Jean Ferrières, Jean Dallongeville, Michel Rossignol, Jacques Bénichou, J. Jaime Caro, Denis Getsios, Luis Hernandez, Lucien Abenhaim & Lamiae Grimaldi-Bensouda. (2016) Model-observational bridging study on the effectiveness of ezetimibe on cardiovascular morbidity and mortality in France: A population-based study. Journal of Clinical Lipidology 10:6, pages 1379-1388.
Crossref
Crossref
Shahnam Sharif, Yolanda van der Graaf, Hendrik M. Nathoe, Harold W. de Valk, Frank L.J. Visseren & Jan Westerink. (2016) HDL Cholesterol as a Residual Risk Factor for Vascular Events and All-Cause Mortality in Patients With Type 2 Diabetes. Diabetes Care 39:8, pages 1424-1430.
Crossref
Crossref
Xavier Pintó & María Carmen García Gómez. (2016) Nuevos tratamientos para la hipercolesterolemia. Medicina Clínica 146:4, pages 172-177.
Crossref
Crossref
Xavier Pintó & María Carmen García Gómez. (2016) New agents for hypercholesterolemia. Medicina Clínica (English Edition) 146:4, pages 172-177.
Crossref
Crossref
Seth S. Martin, Parag H. Joshi & Erin D. Michos. 2016. Translational Research in Coronary Artery Disease. Translational Research in Coronary Artery Disease
67
80
.
Patrick Wainwright, Aidan Ryan, Rasaq Olufadi & Christopher D Byrne. 2005. Encyclopedia of Life Sciences. Encyclopedia of Life Sciences
1
12
.
Aidan Ryan & Christopher D. Byrne. (2015) Importance of early recognition of heterozygous familial hypercholesterolaemia. Current Opinion in Lipidology 26:4, pages 298-303.
Crossref
Crossref
Ángel A. García, Óscar Múñoz, Daniel G. Fernández, Angélica M. Higuera, Álvaro J. Ruiz, Pablo A. Montoya, Juan M. Toro, Juan M. Arteaga, Alonso M. Villamizar, Gregorio Sánchez & Yadira Villalba. (2015) Alternativas terapéuticas al manejo farmacológico con estatinas en adultos con dislipidemia. Revisión sistemática de la literatura y recomendaciones generales. Revista Colombiana de Cardiología 22:4, pages 179-186.
Crossref
Crossref
Tonko Dražić, Vinay Sachdev, Christina Leopold, Jay V. Patankar, Martina Malnar, Silva Hećimović, Sanja Levak-Frank, Ivan Habuš & Dagmar Kratky. (2015) Synthesis and evaluation of novel amide amino-β-lactam derivatives as cholesterol absorption inhibitors. Bioorganic & Medicinal Chemistry 23:10, pages 2353-2359.
Crossref
Crossref
Rashmi Thapa, Suresh Sharma, Vinodh Jeevanantham, Casper Hu, Taylor Myers, James L. Vacek, Buddhadeb Dawn & Kamal Gupta. (2015) Disparities in lipid control and statin drug use among diabetics with noncoronary atherosclerotic vascular disease vs those with coronary artery disease. Journal of Clinical Lipidology 9:2, pages 241-246.
Crossref
Crossref
Shizuya Yamashita, Daisaku Masuda & Akifumi Matsuyama. 2015. Dyslipidemias. Dyslipidemias
465
481
.
Tonko Dražić, Krešimir Molčanov, Vinay Sachdev, Martina Malnar, Silva Hećimović, Jay V. Patankar, Sascha Obrowsky, Sanja Levak-Frank, Ivan Habuš & Dagmar Kratky. (2014) Novel amino-β-lactam derivatives as potent cholesterol absorption inhibitors. European Journal of Medicinal Chemistry 87, pages 722-734.
Crossref
Crossref
P. Deharo, M. Pankert, J. Quilici, C. Grosdidier, V. Verdier, G. Bonnet, P. Morange, M.-C. Alessi, J.-L. Bonnet & T. Cuisset. (2014) Safety and effectiveness of the association ezetimibe-statin (E-S) versus high dose rosuvastatin after acute coronary syndrome: The SAFE-ES study. Annales de Cardiologie et d'Angéiologie 63:4, pages 222-227.
Crossref
Crossref
Genovefa Kolovou, Georgia Ragia, Vana Kolovou, Constantinos Mihas, Niki Katsiki, Ioannis Vasiliadis, Sophie Mavrogeni, Vassiliki Vartela, Anna Tavridou & Vangelis G. Manolopoulos. (2014) Impact of CYP3A5 Gene Polymorphism on Efficacy of Simvastatin. The Open Cardiovascular Medicine Journal 8:1, pages 12-17.
Crossref
Crossref
Anton P. van de Woestijne, Yolanda van der Graaf, Paul I. W. de Bakker, Folkert W. Asselbergs, Gert Jan de Borst, Ale Algra, Wilko Spiering & Frank L. J. Visseren. (2014) LDL-c-linked SNPs are associated with LDL-c and myocardial infarction despite lipid-lowering therapy in patients with established vascular disease. European Journal of Clinical Investigation 44:2, pages 184-191.
Crossref
Crossref
Ioanna Xanthopoulou, Periklis Davlouros, Simos Siahos, Angelos Perperis, Evangelia Zaharioglou & Dimitrios Alexopoulos. (2013) First-line treatment patterns and lipid target levels attainment in very high cardiovascular risk outpatients. Lipids in Health and Disease 12:1.
Crossref
Crossref
Hiromichi Suzuki, Yusuke Watanabe, Hiroo Kumagai & Hiroshi Shuto. (2013)
Comparative efficacy and adverse effects of the addition of ezetimibe to statin
versus
statin titration in chronic kidney disease patients
. Therapeutic Advances in Cardiovascular Disease 7:6, pages 306-315.
Crossref
Crossref
Anton P. van de Woestijne, Yolanda van der Graaf, An-Ho Liem, Maarten J.M. Cramer, Jan Westerink & Frank L.J. Visseren. (2013) Low High-Density Lipoprotein Cholesterol Is Not a Risk Factor for Recurrent Vascular Events in Patients With Vascular Disease on Intensive Lipid-Lowering Medication. Journal of the American College of Cardiology 62:20, pages 1834-1841.
Crossref
Crossref
Antonio M. GottoJrJr & Jennifer E. Moon. (2013) Pharmacotherapies for lipid modification: beyond the statins. Nature Reviews Cardiology 10:10, pages 560-570.
Crossref
Crossref
Juan Pedro-Botet, José M. Mostaza, Xavier Pintó & José R. Banegas. (2013) Consecución del objetivo terapéutico del colesterol de las lipoproteínas de baja densidad en las unidades de lípidos y riesgo vascular de la Sociedad Española de Arteriosclerosis. Clínica e Investigación en Arteriosclerosis 25:4, pages 155-163.
Crossref
Crossref
Mariëtte Y.M. van der Wulp, Henkjan J. Verkade & Albert K. Groen. (2013) Regulation of cholesterol homeostasis. Molecular and Cellular Endocrinology 368:1-2, pages 1-16.
Crossref
Crossref
Livia Pisciotta, Antonella Bellocchio & Stefano Bertolini. (2012) Nutraceutical pill containing berberine versus ezetimibe on plasma lipid pattern in hypercholesterolemic subjects and its additive effect in patients with familial hypercholesterolemia on stable cholesterol-lowering treatment. Lipids in Health and Disease 11:1.
Crossref
Crossref
Michael S Kostapanos, Dimitri P Mikhailidis & Moses S Elisaf. (2012) Adding ezetimibe to statin treatment: is LDL-C lowering the only benefit?. Future Cardiology 8:6, pages 813-817.
Crossref
Crossref
X. Pintó. (2012) El largo trecho para llegar a los objetivos en el tratamiento de las dislipemias. Revista Clínica Española 212:10, pages 488-490.
Crossref
Crossref
. (2012) Current World Literature. Current Opinion in Lipidology 23:4, pages 386-391.
Crossref
Crossref
Doralisa Morrone, William S. Weintraub, Peter P. Toth, Mary E. Hanson, Robert S. Lowe, Jianxin Lin, Arvind K. Shah & Andrew M. Tershakovec. (2012) Lipid-altering efficacy of ezetimibe plus statin and statin monotherapy and identification of factors associated with treatment response: A pooled analysis of over 21,000 subjects from 27 clinical trials. Atherosclerosis 223:2, pages 251-261.
Crossref
Crossref
. (2012) Current World Literature. Current Opinion in Cardiology 27:4, pages 441-454.
Crossref
Crossref
Takamitsu Nakamura, Mitsumasa Hirano, Yoshinobu Kitta, Daisuke Fujioka, Yukio Saito, Ken-ichi Kawabata, Jun-ei Obata, Yosuke Watanabe, Kazuhiro Watanabe & Kiyotaka Kugiyama. (2012) A comparison of the efficacy of combined ezetimibe and statin therapy with doubling of statin dose in patients with remnant lipoproteinemia on previous statin therapy. Journal of Cardiology 60:1, pages 12-17.
Crossref
Crossref
Michael S. Kostapanos, Moses S. Elisaf & Dimitri P. Mikhailidis. (2012) Ezetimibe – a new approach in hypercholesterolemia management. Pharmacological Reports 64:4, pages 997-998.
Crossref
Crossref
Peter P. Toth, Christie M. Ballantyne, Michael H. Davidson, Joanne E. Tomassini, Dena Rosen Ramey, David Neff, Andrew M. Tershakovec, X. Henry Hu & Kaan Tunceli. (2012) Changes in prescription patterns before and after reporting of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression trial (ENHANCE) results and expected effects on low-density lipoprotein-cholesterol reduction. Journal of Clinical Lipidology 6:2, pages 180-191.
Crossref
Crossref
Katherine A. Lyseng-Williamson. (2012) Ezetimibe/Simvastatin: A Guide to its Clinical Use in Hypercholesterolemia. American Journal Cardiovascular Drugs 12:1, pages 49-56.
Crossref
Crossref
Seth S. Martin, Roger S. Blumenthal & Michael Miller. (2012) LDL Cholesterol: The Lower the Better. Medical Clinics of North America 96:1, pages 13-26.
Crossref
Crossref
Tuyyab Hassan, Ayan Rage, Sowjanya Kanna & Zaid Ul Hassan. (2012) When It Comes to Reducing Cholesterol, Not All Statins Are the Same. The American Journal of Medicine 125:1, pages e13.
Crossref
Crossref
Chen-Fang Lin, Fei-Yuan Hsiao & Li-Jiuan Shen. (2011) The authors respond:. Clinical Therapeutics 33:12, pages 2092.
Crossref
Crossref
Niki Katsiki, Eirini Lioudaki, Emmanuel S. Ganotakis & Dimitri P. Mikhailidis. (2011) Impact of Ezetimibe Coadministered With Statins on Cardiovascular Events Following Acute Coronary Syndrome: A 3-Year Population-Based Retrospective Cohort Study in Taiwan. Clinical Therapeutics 33:12, pages 2091.
Crossref
Crossref